Status:
COMPLETED
Pericapsular Nerve Group Block Chemical Neurolysis in Advanced Hip Osteoarthritis
Lead Sponsor:
Poznan University of Medical Sciences
Conditions:
Osteoarthritis
Osteoarthritis, Hip
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
PENG neurolysis in advanced osteoarthritis of the hip joint.
Detailed Description
The study aims to assess the safety and effectiveness of regional pain treatment methods and their impact on the quality of life of patients with advanced osteoarthritis of the hip joint.
Eligibility Criteria
Inclusion
- Patients of the Pain Treatment Clinic of the Transfiguration of Jesus Clinical Hospital of the Medical University of Poznań will be qualified for the study
- patients with coxarthrosis or gonarthrosis who failed to achieve satisfactory pain control (NRS\>3) despite the use of NSAIDs, Paracetamol, and co-analgetics
- Age of patients: from 18 to 110 years of age.
- Caucasian patients can give informed, complete, written consent.
Exclusion
- suspected or diagnosed opioid dependence syndrome
- active cancer
- dementia
Key Trial Info
Start Date :
October 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 14 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06087588
Start Date
October 17 2023
End Date
January 14 2025
Last Update
January 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Poznan University of Medical Sciences
Poznan, Poznań, Poland, 61-701